Anti-TNF

This large real-world study found upadacitinib was associated with lower risk of treatment failure and more corticosteroid-free stability compared with several other advanced therapies for ulcerative colitis —...

Children with IBD and their caregivers may be interested in subcutaneous infliximab as an alternative to regular IV infusions because this review suggests it can maintain drug levels and remission after switching, with...

Hospitalized patients with acute severe ulcerative colitis often need rescue therapy to avoid colectomy.

The trial suggests starting infliximab early can delay the need for further biologic escalation in children with moderate-to-severe Crohn’s disease, and that stopping anti‑TNF after induction often leads to relapse.

Cure8 could only read part of this source from American Journal of Therapeutics, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Infliximab, and Ustekinumab.

A PopPK model for subcutaneous infliximab could enable more personalized dosing when starting or switching patients to home-administered infliximab, potentially improving drug exposure and management for people with IBD.

Perianal fistulas are a common, hard-to-heal complication of Crohn's disease. This review collects current options beyond infliximab and explains where evidence is stronger or still emerging, which can help patients and...

People with IBD often need long-term advanced therapies. Cancer risk concerns commonly influence treatment choices—this review compiles current evidence to help patients and clinicians weigh risks when starting or...

This study compares first‑line vedolizumab versus TNF antagonist strategies in biologic‑naive ulcerative colitis patients over multiple years — information that could affect treatment choice and expectations about...

This post‑marketing study will add safety and real‑world effectiveness information about Tabellvi® (adalimumab) in Chinese adults with moderate to severe Crohn's disease, which can inform patients and clinicians using or...

The study suggests active smoking reduces the effectiveness of anti-TNF biologics in people with IBD, which could affect treatment response and the need to switch or escalate therapies. This supports including smoking...

Patients and clinicians often face trade-offs when managing overlapping immune-mediated diseases. This report shows how past thromboembolic events and disease remission status can steer therapy away from JAK inhibitors...

Dose increases are common during IBD maintenance and vary a lot by drug and patient profile. Knowing which treatments and patient factors are linked to escalation can help patients and clinicians plan monitoring and...

Perianal fistulising Crohn's disease is hard to treat and often fails anti-TNF drugs. This study will provide real-world data on whether upadacitinib can be effective and safe for patients with refractory perianal...

This study compares two commonly used biologics as first-line therapy for moderate-to-severe ulcerative colitis and reports better short- and long-term effectiveness for vedolizumab with similar safety. The results could...

Identifying a genetic cause (XIAP frameshift variant) helped explain why anti‑TNF drugs failed and why blocking IL‑12/23 with ustekinumab led to improvement; that connection could influence treatment choices for similar...

Early prediction of who will not respond to infliximab could help clinicians avoid prolonged ineffective treatment, enabling earlier reassessment and changes in therapy as part of treat-to-target care.

Patients and clinicians often need evidence about whether switching from ustekinumab to an anti‑TNF (infliximab or adalimumab) still gives meaningful clinical responses. This study suggests many patients can respond, but...

Refractory IBD in children is linked to growth and development problems, hospitalizations, and surgery; knowing treatment options after anti‑TNF failure matters for long‑term outcomes. The review highlights which...

This study directly compares two rescue medications used when intravenous steroids fail in acute severe ulcerative colitis, reporting similar short-term remission and safety but a slower early response with tacrolimus —...

Orofacial granulomatosis often co-occurs with Crohn's disease and appears linked to a distinct Crohn's phenotype and treatment needs. The findings suggest that advanced therapies can be effective for OFG-associated CD...

The project investigates how TNFR1 and TNFR2 differently control epithelial repair in the colon—mechanisms that may explain why many patients on anti‑TNF biologics do not achieve lasting mucosal healing and could point...

The study identifies epithelial IFN‑I signaling as a driver of barrier failure in anti‑TNF refractory Crohn’s disease and suggests that blocking IFN‑I could be a rescue strategy for patients who do not respond to...

The study suggests starting anti-TNF therapy with an immunomodulator at diagnosis may reduce surgery, hospital stays, and progression to complicated Crohn’s over 5 years — outcomes that matter to patients and clinicians...

A blood biomarker that helps predict primary non-response to anti‑TNF drugs could spare some patients ineffective therapy, reduce delays to alternative treatments, and inform shared decision‑making before starting...

The findings give clinicians and patients data on how often biologic therapy leads to endoscopic remission in biologic‑naïve patients with isolated small‑bowel Crohn's disease, and they suggest similar effectiveness...

This trial tests whether starting with one biologic or targeted therapy versus another (and the sequence of switches) affects remission, safety, and quality of life for people with moderate-to-severe ulcerative colitis —...

The findings suggest people with IBD on IV infliximab could switch to fixed-dose SC infliximab without losing drug exposure, and many may gain convenience and higher trough drug levels regardless of concomitant...

The analysis compares rescue drugs used when severe ulcerative colitis doesn't respond to IV steroids — a high-stakes situation where avoiding colectomy matters.

Head-to-head comparisons between biologics are uncommon but useful for patients and clinicians deciding between agents. This study specifically compares ustekinumab and infliximab for remission, safety, and quality of...

Patients and clinicians often need real-world data on how methotrexate is actually used in IBD outside trials—this study shows it’s commonly paired with biologics, usually given subcutaneously, and has a median use of...

Pediatric-onset IBD can behave differently than adult-onset disease. Comparing conventional versus biologic approaches in children may help clarify relative effectiveness, safety, and impacts on growth and steroid...

If true, using infliximab drug-level modeling plus routine blood tests could help predict who has mucosal healing without immediate endoscopy, potentially reducing invasive procedures and improving monitoring for people...

People with IBD and their clinicians need to know whether common IBD treatments change COVID-19 risk or should be stopped. This review provides practical recommendations (continue most maintenance drugs; avoid systemic...

The work identifies factors that predict loss of response to infliximab and suggests maintenance drug levels are the strongest predictor, which could influence monitoring strategies for people with Crohn's disease on...

Serum LRG1 is a candidate blood biomarker for mucosal inflammation in UC, but anti-TNF drugs may suppress its levels and cause false-negative results. This affects noninvasive monitoring and decisions based on LRG1...

A non-invasive test (intestinal ultrasound) that predicts whether patients stay on biologic therapy could reduce the need for frequent endoscopy and help guide monitoring decisions.

This study suggests that cumulative infliximab exposure over time (AUC) — not just trough levels — may predict infection risk in people with IBD. That could affect how clinicians use therapeutic drug monitoring to...

The 5-year PROFILE follow-up is presented as strong evidence that early, effective therapy (in this case infliximab plus an immunomodulator) can change the long-term course of Crohn’s disease by lowering surgery rates...

This analysis directly addresses treatments commonly used for perianal fistulizing Crohn’s disease and compares biologic anti-TNF drugs with emerging mesenchymal stem cell therapy, information that could affect treatment...

This article explains why two widely used IBD drugs from AbbVie (Skyrizi and Rinvoq) are central to the company’s growth and describes ongoing development efforts that could expand treatment options and indications in...

Knowing a patient’s estimated infliximab clearance before starting rescue therapy for acute severe ulcerative colitis could help identify who may need higher or intensified induction dosing and who might be at greater...

People with IBD who are treated with anti‑TNFα drugs commonly develop inflammatory or infectious skin problems. This study aims to clarify whether Staphylococcus aureus is more abundant in those lesions and whether its...

This trial studies adalimumab safety and pediatric dosing in children with moderate–severe Crohn's disease, which is directly relevant to families and clinicians considering anti-TNF therapy for pediatric IBD.

Patients and clinicians want to know whether tofacitinib raises blood clotting or platelet activation risk in ulcerative colitis, because similar safety concerns were reported in other diseases.

The study explores using coordinated, longitudinal multi-omic profiles to better detect true responses to anti-TNF therapy and to inform personalized treatment selection for people with IBD.

Real-world 52-week data suggest mirikizumab can produce meaningful remission and reasonable drug persistence in patients with treatment-experienced ulcerative colitis. This is especially relevant for people who have not...

Patients with moderate-to-severe Crohn's disease who do not respond to anti-TNF drugs have limited options. This study suggests combining ustekinumab with upadacitinib may improve endoscopic healing versus either drug...